Evidence map›Paper›PMID 29022201›Full record

ArticleInternational journal of hematology2018

Increased mean platelet volume (MPV) is an independent predictor of inferior survival in patients with primary and secondary myelofibrosis.

Marko Lucijanic, Zdravko Mitrovic, David Cicic, Zeljko Prka, Vlatko Pejsa, Ana Livun, Tajana Stoos-Veic, Zeljko Romic, Marcela Zivkovic, Iva Lucijanic and 2 more

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Sclerostin Depletion Induces Inflammation in the Bone Marrow of Mice.International journal of molecular sciences · 2021
    Article
  3. Platelets as messengers of early-stage cancer.Cancer metastasis reviews · 2021
    Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Marko LucijanicHematology Department, University Hospital Dubrava, Av. Gojka Suska 6, 10000, Zagreb, Croatia. markolucijanic@yahoo.com.ORCID http://orcid.org/0000-0002-1372-2040
Zdravko MitrovicHematology Department, University Hospital Dubrava, Av. Gojka Suska 6, 10000, Zagreb, Croatia.
David CicicHematology Department, University Hospital Dubrava, Av. Gojka Suska 6, 10000, Zagreb, Croatia.
Zeljko PrkaHematology Department, University Hospital Dubrava, Av. Gojka Suska 6, 10000, Zagreb, Croatia.
Vlatko PejsaHematology Department, University Hospital Dubrava, Av. Gojka Suska 6, 10000, Zagreb, Croatia.
Ana LivunDivision of Molecular Diagnosis and Genetics, Clinical Department of Laboratory Diagnostics, University Hospital Dubrava, Zagreb, Croatia.
Tajana Stoos-VeicDepartment of Clinical Cytology and Cytometry, University Hospital Dubrava, Zagreb, Croatia.
Zeljko RomicClinical Department of Laboratory Diagnostics, University Hospital Dubrava, Zagreb, Croatia.
Marcela ZivkovicClinical Department of Laboratory Diagnostics, University Hospital Dubrava, Zagreb, Croatia.
Iva LucijanicSchool of Medicine, University of Zagreb, Zagreb, Croatia.
Zrinka FabrisRadiology Department, General Hospital Dubrovnik, Dubrovnik, Croatia.
Rajko KusecHematology Department, University Hospital Dubrava, Av. Gojka Suska 6, 10000, Zagreb, Croatia.
University Hospital Dubrava · HRUniversity of Zagreb · HRUniversity of Dubrovnik · HR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neoplastic megakaryopoiesis is a dominant feature of Philadelphia-chromosome-negative myeloproliferative neoplasms (Ph- MPNs), and elevated mean-platelet-volume (MPV) is a common finding in these diseases. The clinical and prognostic significances of MPV in patients with primary (PMF) and secondary myelofibrosis (SMF) have not been reported. We retrospectively analyzed 87 patients with myelofibrosis (66 with PMF, 21 with SMF) treated at our institution. MPV was recorded in addition to other hematological and clinical parameters. MPV was elevated in both PMF and SMF patients in comparison to controls, whereas there was no statistically significant difference between PMF and SMF. Elevated MPV was associated with lower platelets (P = 0.016), higher white blood cells (P = 0.015), higher percentage of circulatory blasts (P = 0.009), higher lactate dehydrogenase (P = 0.011), larger spleen size (P = 0.014) and higher Dynamic International Prognostic score category (P = 0.027), while there was no statistically significant association with driver mutations or degree of bone marrow fibrosis. Higher MPV was univariately associated with inferior overall survival in the whole cohort (HR = 3.82, P = 0.006), PMF (HR = 4.35, P = 0.007) and SMF patients (HR = 7.22, P = 0.034). These associations remained significant in multivariate analyses adjusted for DIPSS. Higher MPV is associated with more aggressive disease features and exhibits powerful independent prognostic properties in both PMF and SMF settings.

Indexed as

Mean Platelet VolumeAgedBiomarkersCohort StudiesDisease ProgressionFemaleHumansMaleMiddle AgedMultivariate AnalysisPredictive Value of TestsPrimary MyelofibrosisPrognosisRetrospective StudiesSurvival RateBiomarkersMean platelet volumePhiladelphia chromosome negative myeloproliferative neoplasmPrimary myelofibrosisSurvival

Identifiers

PMID29022201
OpenAlexW2760823392

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.